Option Delisting: Astria Therapeutics (ATXS) to be Delisted
Astria Therapeutics (ATXS) will have its options delisted effective January 26th, a change impacting trading strategies. The biopharmaceutical company focuses on developing therapies for rare allergic and immunological diseases, such as hereditary angioedema and atopic dermatitis. Despite a strong liquidity position, the company faces significant financial challenges, including negative EPS and operating margins, alongside high valuation ratios.
Astria Therapeutics Announces Management and Board Changes Following Merger
Astria Therapeutics, Inc. announced significant management and board changes effective January 23, 2026, following a merger. Several directors and executive officers resigned, and new individuals were appointed to various roles including CEO, CFO, COO, CMO, General Counsel, VP of HR, President, and Secretary. These changes were a direct result of the merger.
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Hold" from Brokerages
Astria Therapeutics, Inc. (NASDAQ:ATXS) has received a consensus "Hold" rating from eleven brokerages, with an average target price of $24.50. Several analysts recently downgraded the stock after the company missed quarterly expectations for both EPS and revenue. Institutional investors hold a significant portion of ATXS stock, with several major funds increasing their positions in the third quarter.
Astria Therapeutics Announced Transfer or Voluntary Withdrawal of Listing
Astria Therapeutics (ATXS) announced on January 23, 2026, that it has notified Nasdaq of its merger closing and requested the suspension of trading. The company has also asked Nasdaq to file a Form 25 for delisting and deregistration of its common stock, and plans to file a Form 15 to terminate registration and suspend reporting obligations. This action follows the consummation of its merger.
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below Fifty Day Moving Average - Here's What Happened
Astria Therapeutics (NASDAQ:ATXS) shares fell below their fifty-day moving average, trading as low as $12.45 before closing at $12.81, below the $12.77 average. This drop follows multiple analyst downgrades, resulting in a consensus "Hold" rating and an average price target of $24.50. The company also missed recent quarterly earnings and revenue expectations, reporting an EPS of -$0.55 against an expected -$0.41 and revenue of $0.71M compared to a $10.67M forecast.
Why (ATXS) Price Action Is Critical for Tactical Trading
This article analyzes Astria Therapeutics Inc. (NASDAQ: ATXS) focusing on its price action as critical for tactical trading. It highlights a weak near-term sentiment despite long-term strength, noting an exceptional risk-reward short setup. The analysis provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for different horizons.
BioCryst Announces Preliminary Full Year 2025 ORLADEYO®
BioCryst Pharmaceuticals announced preliminary unaudited ORLADEYO net revenue for Q4 and full year 2025, exceeding prior guidance with $601 million. The company projects ORLADEYO net revenue for 2026 to be between $625 million and $645 million, expecting continued non-GAAP profitability even with the planned acquisition of Astria Therapeutics. BioCryst will present these results and its outlook at the 44th Annual J.P. Morgan Healthcare Conference.
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Astria Therapeutics, Inc. (ATXS) to BioCryst Pharmaceuticals, Inc. (BCRX). The law firm is examining whether the offered consideration of $8.55 cash and 0.59 shares of BioCryst common stock per Astria share adequately values the company and if the sales process was fair. Shareholders believing the transaction undervalues Astria are encouraged to contact KSF to discuss their legal rights.
Astria Therapeutics’ STAR-0310 Study: A Promising Step Forward
The provided article is incomplete, so a summary cannot be generated. It only contains a title and source, without any body content to analyze.
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR
Monteverde & Associates PC, a class action firm, is investigating several mergers for potential shareholder claims. These include the sales of Astria Therapeutics, Inc. (ATXS) to BioCryst Pharmaceuticals, Inc., Middlefield Banc Corp. (MBCN) to Farmers National Banc Corp., and Semrush Holdings, Inc. (SEMR) to Adobe Inc. Shareholders of these companies are encouraged to contact the firm for more information regarding their rights and the proposed transaction terms.
Technical Reactions to ATXS Trends in Macro Strategies
This article provides a technical analysis of Astria Therapeutics Inc. (NASDAQ: ATXS) based on AI models from Stock Traders Daily. It highlights weak near-term sentiment but strong mid- and long-term signals, and outlines three distinct trading strategies for different risk profiles. The analysis includes support and resistance levels across multiple timeframes and emphasizes the predictive AI's ability to offer real-time signals and risk management for institutional and individual traders.
BioCryst Pharmaceuticals announces board chair transition following retirement notice
BioCryst Pharmaceuticals announced that Dr. Nancy J. Hutson will retire from its Board of Directors and step down as board chair, with Vincent J. Milano elected as her successor. This transition is expected to occur upon the closing of BioCryst’s proposed acquisition of Astria Therapeutics or at the company's 2026 annual meeting. The announcement comes amidst other company developments, including Q3 2025 earnings results and antitrust clearance for the Astria Therapeutics acquisition.
Astria Therapeutics, Inc. $ATXS Shares Acquired by JPMorgan Chase & Co.
JPMorgan Chase & Co. significantly increased its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 4,607.1% in the second quarter, now owning 1,696,071 shares valued at $9.09 million. This comes as Astria Therapeutics reported disappointing Q results, missing EPS and revenue estimates. Despite mixed analyst ratings, institutional investors largely control the company's shares.
Panagora Asset Management Inc. Purchases New Holdings in Astria Therapeutics, Inc. $ATXS
Panagora Asset Management Inc. recently acquired a new position of 98,458 shares in Astria Therapeutics, Inc. (NASDAQ:ATXS) valued at $528,000. Other institutions like JPMorgan Chase & Co. and ADAR1 Capital Management LLC significantly increased their stakes, leading to institutional ownership of 98.98%. Despite a consensus "Hold" rating from analysts with a $24.50 price target, the biotechnology company recently missed EPS and revenue estimates, and its stock trades around $12.93.
Affinity Asset Advisors LLC Purchases Shares of 300,000 Astria Therapeutics, Inc. $ATXS
Affinity Asset Advisors LLC has acquired 300,000 shares of Astria Therapeutics, Inc. (NASDAQ:ATXS), a new position valued at approximately $1.61 million, meaning institutional investors now own 98.98% of the company. Despite recent downgrades from analysts and missed quarterly earnings estimates, the stock is trading near its 52-week high with a market cap of about $738 million. The consensus rating from analysts is "Hold" with an average target price of $24.50.
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Hold" from Analysts
Astria Therapeutics, Inc. (NASDAQ:ATXS) has received an average "Hold" rating from eleven analysts, with a 12-month average price target of $24.50. The biotechnology company recently reported earnings per share of ($0.55), missing the consensus estimate, and had revenue of $0.71 million against an expected $10.67 million. Institutional investors own approximately 98.98% of the stock.
Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates
Astria Therapeutics, Inc. (ATXS) reported a Q3 loss of $0.55 per share, missing the Zacks Consensus Estimate of a $0.41 loss, and also fell short of revenue expectations with $0.71 million against an estimated $16.1 million. Despite the disappointing quarter, the company's shares have risen nearly 40% year-to-date. The stock currently holds a Zacks Rank #3 (Hold) due to a mixed earnings outlook.
Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates
Astria Therapeutics, Inc. (ATXS) reported a Q3 loss of $0.55 per share, missing the Zacks Consensus Estimate of a $0.41 loss, and revenues of $0.71 million, falling short of estimates by 95.59%. The company's stock has outperformed the S&P 500 year-to-date, but its immediate price movement hinges on management's commentary. Astria Therapeutics currently holds a Zacks Rank #3 (Hold) based on mixed estimate revisions.
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Astria Therapeutics announced its Q3 2025 financial results and a corporate update, including BioCryst's upcoming acquisition of Astria. The company detailed progress on its lead programs, navenibart (STAR-0215) for HAE, with its Phase 3 trial progressing and strong final Phase 1b/2 results, and STAR-0310 for atopic dermatitis, which showed promising Phase 1a data. Financially, Astria reported $227.7 million in cash, cash equivalents and short-term investments as of September 30, 2025, and provided a cash runway guidance into 2028.
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $27.14 - Defense World
Brokerages have set an average target price of $27.14 for Astria Therapeutics (NASDAQ:ATXS), with varying ratings including "buy," "overweight," "outperform," and "hold." The company's stock recently dropped by 0.9%, trading at $6.75, and has seen notable institutional investment activity. Astria Therapeutics is a biopharmaceutical company focusing on treatments for allergic and immunological diseases, with its lead product candidate STAR-0215 in clinical trials for hereditary angioedema.
HC Wainwright Downgrades Astria Therapeutics (NASDAQ:ATXS) to Hold - Defense World
HC Wainwright has downgraded Astria Therapeutics (NASDAQ:ATXS) from a "buy" to a "hold" rating. This follows other analyst actions including Cantor Fitzgerald and Evercore ISI maintaining "overweight" and "outperform" ratings respectively, while Oppenheimer lowered its rating to "market perform". The article also details significant institutional inflow into Astria Therapeutics stock.
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
Kahn Swick & Foti, LLC (KSF), led by former Attorney General of Louisiana Charles C. Foti, Jr., Esq., is investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). KSF is examining whether the proposed consideration of $8.55 cash and 0.59 shares of BioCryst common stock per Astria share adequately values Astria Therapeutics and if the process leading to this sale was appropriate. Shareholders are invited to contact KSF to discuss their legal rights if they believe the company is undervalued.
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS - The Globe and Mail
Kahn Swick & Foti, LLC, led by former Attorney General of Louisiana Charles C. Foti, Jr., has launched an investigation into the proposed sale of Astria Therapeutics, Inc. (ATXS). The firm is examining whether the proposed sale price adequately reflects the company's value and if the process was fair. Investors who believe the transaction undervalues the company are encouraged to contact KSF to discuss their legal rights.
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., Esq., is investigating the proposed sale of Astria Therapeutics, Inc. (ATXS). The firm is examining whether the proposed price and process adequately serve shareholder interests. Shareholders who believe the transaction undervalues the company are encouraged to contact KSF to discuss their legal rights.
JMP Securities Reiterates Market Perform Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World
JMP Securities reiterated its "market perform" rating for Astria Therapeutics (NASDAQ:ATXS). Other analysts have also recently adjusted their ratings and price targets for the biotechnology company. Institutional investors have significantly increased or reduced their stakes in Astria Therapeutics during recent quarters.
ATXS Downgraded to Neutral by HC Wainwright & Co. | ATXS Stock News
Astria Therapeutics (ATXS) was downgraded from 'Buy' to 'Neutral' by HC Wainwright & Co. analyst Joseph Pantginis. This downgrade follows several other recent rating adjustments by various analysts. The article also provides an overview of Astria Therapeutics' product pipeline and Wall Street analysts' consensus forecast for the stock.
ATXS Faces Downgrade with Price Target Slashed by Analyst Wedbush | ATXS Stock News
Astria Therapeutics (ATXS) has been downgraded by Wedbush from 'Outperform' to 'Neutral', with a significant reduction in its price target from $28.00 to $13.00 USD. This downgrade follows a similar action by Jefferies and reflects a changing sentiment among analysts despite some previous 'Buy' ratings. The average analyst price target for ATXS is now $27.00, implying a 127.27% upside from its current price of $11.88.
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX - TradingView
Astria Therapeutics (ATXS) stock surged 37.1% following a definitive agreement to be acquired by BioCryst Pharmaceuticals (BCRX) for approximately $700 million, or $13 per share. This acquisition aims to enhance BioCryst's leadership in the hereditary angioedema (HAE) market by adding Astria's lead asset, navenibart, a long-acting monoclonal antibody for HAE prophylaxis. The deal is expected to strengthen BioCryst's pipeline with a potential best-in-class injectable therapy and drive double-digit revenue growth.
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS and RYN on Behalf of Shareholders - GlobeNewswire
Halper Sadeh LLC is investigating Astria Therapeutics, Inc. (ATXS) regarding its sale to BioCryst Pharmaceuticals, Inc., and Rayonier Inc. (RYN) concerning its merger with PotlatchDeltic Corporation. The investigations focus on potential violations of federal securities laws and breaches of fiduciary duties to shareholders, with the firm offering legal representation to seek increased consideration or additional disclosures.
Astria Therapeutics (ATXS) Downgraded by JMP Securities: Latest Analyst Insights | ATXS Stock News - GuruFocus
JMP Securities downgraded Astria Therapeutics (ATXS) to "Market Perform" from "Market Outperform" on October 15, 2025 following a significant price target reduction by Jefferies. This reflects a more cautious outlook for the biopharmaceutical company, despite some analysts maintaining "Buy" or "Overweight" ratings with higher price targets. The average one-year price target from 8 analysts is $27.00, implying a potential upside of 131.56% from its current price.
Astria Therapeutics’ (ATXS) “Hold” Rating Reaffirmed at Jefferies Financial Group - Defense World
Jefferies Financial Group has reaffirmed its "Hold" rating for Astria Therapeutics (ATXS). This comes amidst other analysts issuing "Outperform" or "Buy" ratings and target price increases, leading to an average "Moderate Buy" rating for the stock. Institutional investors have also increased their holdings in the biotechnology company.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ - MarketScreener
Monteverde & Associates PC, a class action law firm, announced an investigation into Astria Therapeutics, Inc. (NASDAQ: ATXS) regarding its proposed sale to BioCryst Pharmaceuticals, Inc. The firm is questioning whether the deal, offering $8.55 cash and 0.59 shares of BioCryst common stock per Astria share, is fair to shareholders and encourages affected shareholders to seek more information. The firm, headquartered in the Empire State Building, emphasizes its track record of recovering funds for shareholders.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS) - PR Newswire
Monteverde & Associates PC has announced an investigation into Astria Therapeutics, Inc. (NASDAQ: ATXS) regarding its proposed sale to BioCryst Pharmaceuticals, Inc. The firm is questioning whether the deal, offering $8.55 in cash and 0.59 shares of BioCryst common stock per Astria share, is fair to shareholders. Monteverde & Associates PC encourages Astria shareholders to seek additional information regarding the fairness of this transaction.
Oppenheimer downgrades Astria Therapeutics stock rating to Perform on BioCryst acquisition - Investing.com Canada
The provided content indicates an application error and does not contain the actual news article. Therefore, a summary of Oppenheimer's downgrade of Astria Therapeutics and the BioCryst acquisition cannot be generated from this content.
Astria Therapeutics (ATXS) Acquisition Sparks Interest in Navenibart - GuruFocus
BioCryst's $700 million acquisition of Astria Therapeutics (ATXS) is highlighted for its focus on navenibart, a promising HAE treatment in Phase 3 trials. Despite market concerns about competition, TD Cowen maintains a positive outlook due to reduced risk. Astria Therapeutics, a clinical-stage biopharmaceutical company, operates in the rare allergic and immunological diseases sector, demonstrating strong financial health but currently reporting no revenue.
Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - The Malaysian Reserve
The Ademi Firm is investigating whether Astria Therapeutics Inc. is securing a fair price for its public shareholders. This investigation suggests concerns regarding the fairness of a potential transaction or valuation for the company's stock.
Oppenheimer downgrades Astria Therapeutics stock rating to Perform on BioCryst acquisition - Investing.com UK
This article indicates an application error that prevented the full content from loading. However, the title suggests that Oppenheimer has downgraded Astria Therapeutics' stock rating to "Perform" following an acquisition by BioCryst. The lack of article content prevents a more detailed summary.
Astria Therapeutics (ATXS) Acquisition Boosts Confidence in BioC - GuruFocus
RBC Capital has increased BioCryst's price target to $15, maintaining an Outperform rating, following BioCryst's acquisition of Astria Therapeutics (ATXS). This acquisition, despite potential short-term dilution, is expected to significantly strengthen BioCryst's capabilities and business foundation, making the recent share price decline a favorable buying opportunity. Astria Therapeutics, a biopharmaceutical company specializing in rare allergic and immunological diseases, brings promising preclinical programs like STAR-0215 for hereditary angioedema and STAR-0310 for atopic dermatitis.
Form 425 Astria Therapeutics, Filed by: BIOCRYST PHARMACEUTICALS INC - StreetInsider
This SEC filing (Form 425) by BioCryst Pharmaceuticals Inc. relates to the proposed acquisition of Astria Therapeutics, Inc. The document includes communications posted on social media platforms X and LinkedIn regarding the merger, as well as crucial cautionary statements about forward-looking information, the potential risks involved in the merger, and a guide on where to find additional important information for investors.
ATXS Rating Downgraded: Jefferies Lowers Price Target | ATXS Stock News
Jefferies downgraded Astria Therapeutics (ATXS) from "Buy" to "Hold" and significantly lowered its price target from $30.00 to $13.00, a 56.67% decrease. This contrasts with more optimistic ratings from other analysts over recent months, who had largely maintained or raised price targets for the biopharmaceutical company. The average target price from 9 analysts is now $29.89, implying a 154.59% upside from the current price.
ATXS Rating Downgraded: Jefferies Lowers Price Target | ATXS Stock News
Jefferies downgraded Astria Therapeutics (ATXS) from "Buy" to "Hold" and significantly cut its price target from $30.00 to $13.00. This downgrade contrasts with recent positive ratings from other analysts which had maintained or raised price targets. Investors are now closely watching how this change in sentiment will impact ATXS's stock performance, given the company's focus on developing therapies for rare allergic and immunological diseases.
ATXS Stocks Flying High: Too Late to Buy? - StocksToTrade
Astria Therapeutics Inc. (ATXS) stock surged by 41.07% due to positive trial results for its angioedema treatments, navenibart and STAR-0310. Despite current financial losses common for R&D-heavy biotech firms, strong balance sheets and promising clinical advancements indicate potential long-term growth and investor confidence, with analysts raising price targets. The article discusses key developments, financial reports, and future outlook for the company, emphasizing the importance of a comprehensive trading plan.
BioCryst To Acquire Astria Therapeutics - citybiz
BioCryst Pharmaceuticals announced its acquisition of Astria Therapeutics for approximately $700 million in enterprise value, comprising cash and stock. This acquisition aims to expand BioCryst's hereditary angioedema (HAE) portfolio with Astria's lead product candidate, navenibart, a late-stage injectable therapy, and is expected to close in Q1 2026. The deal positions BioCryst to offer both oral and injectable HAE treatments, enhancing its long-term revenue growth and maintaining a strong financial profile.
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
BioCryst Pharmaceuticals announced its definitive agreement to acquire Astria Therapeutics for approximately $920 million in equity value and $700 million in enterprise value. This acquisition will add navenibart, a late-stage plasma kallikrein inhibitor for hereditary angioedema (HAE) prophylaxis, to BioCryst's portfolio, enhancing its offerings in HAE treatments. The deal is expected to solidify BioCryst's double-digit HAE portfolio growth, maintain profitability, and be cash flow positive post-transaction, with a closing anticipated in Q1 2026.
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
Astria Therapeutics announced positive initial results from its Phase 1a trial of STAR-0310, an OX40 antagonist, in healthy subjects. The drug demonstrated a best-in-class half-life of 68 days, supporting potential every-six-month administration, alongside durable cytokine inhibition and good tolerability with no ADCC-related side effects. These findings suggest STAR-0310 has the potential for a wider therapeutic window and greater efficacy for atopic dermatitis patients compared to existing treatments.
Astria Therapeutics, Inc. (ATXS) Now Trades Above Golden Cross: Time to Buy?
Astria Therapeutics, Inc. (ATXS) has just experienced a "golden cross," where its 50-day simple moving average crossed above its 200-day simple moving average, indicating a potential bullish breakout. The stock has rallied 19.8% over the past four weeks, and with positive earnings outlook and higher consensus estimates, ATXS could be poised for further growth. Investors are encouraged to add ATXS to their watchlist.
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Astria Therapeutics (NASDAQ:ATXS) reported Q1 2024 financial results and provided a corporate update, highlighting positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 trial for STAR-0215 in HAE, supporting potential quarterly and bi-annual administration. The company plans to advance STAR-0215 to a pivotal Phase 3 trial in Q1 2025 and is progressing STAR-0310 for atopic dermatitis towards an IND submission by year-end 2024. Astria also reported increased net loss and operating expenses for the quarter, but maintains a strong cash position expected to fund operations into mid-2027.
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Astria Therapeutics announced its Q4 and full-year 2023 financial results and provided a corporate update, highlighting progress in its STAR-0215 program for HAE with initial proof-of-concept data expected in Q1 2024 and STAR-0310 for atopic dermatitis on track for an IND submission by year-end 2024. The company reported a cash position of $246.5 million as of December 31, 2023, with sufficient funds to operate into mid-2027 following a February 2024 underwritten offering of $125.0 million. Financials included increased R&D and G&A expenses, resulting in an operating loss of $83.0 million and a net loss of $72.9 million for the full year 2023.
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
Astria Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for STAR-0310, a monoclonal antibody OX40 antagonist intended for atopic dermatitis treatment. A Phase 1a trial in healthy volunteers is expected to begin in Q1 2025, with early proof-of-concept results anticipated in Q3 2025, and results in atopic dermatitis patients by Q2 2026. The company believes STAR-0310 has the potential for a wider therapeutic window and infrequent dosing due to its design and long half-life.
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Astria Therapeutics released its third-quarter 2024 financial results and provided a corporate update, highlighting progress for both navenibart (STAR-0215) for hereditary angioedema (HAE) and STAR-0310 for atopic dermatitis (AD). The company anticipates initiating a Phase 3 trial for navenibart in Q1 2025 and submitting an IND for STAR-0310 by year-end 2024. Astria reported $344.3 million in cash, cash equivalents, and short-term investments as of September 30, 2024, sufficient to fund operations into mid-2027.
